{"id":"https://openalex.org/W2014684792","doi":"https://doi.org/10.1517/13543784.2013.754422","title":"Perifosine in renal cell carcinoma","display_name":"Perifosine in renal cell carcinoma","publication_year":2012,"publication_date":"2012-12-20","ids":{"openalex":"https://openalex.org/W2014684792","doi":"https://doi.org/10.1517/13543784.2013.754422","mag":"2014684792","pmid":"https://pubmed.ncbi.nlm.nih.gov/23253151"},"language":"en","primary_location":{"id":"doi:10.1517/13543784.2013.754422","doi":"https://doi.org/10.1517/13543784.2013.754422","is_oa":false,"landing_page_url":"https://doi.org/10.1517/13543784.2013.754422","pdf_url":null,"source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2014684792"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5087977862","display_name":"Neeharika Srivastava","orcid":"https://orcid.org/0000-0001-5217-852X","observed_orcids":["https://orcid.org/0000-0001-5217-852X"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neeharika Srivastava","raw_affiliation_strings":["Beth Israel Deaconess Medical Center, Division of Hematology and Oncology, 330 Brookline Avenue, MASCO 4th Floor, Boston, MA 02215, USA","+1 617 632 9260","Beth Israel Deaconess Medical Center, Division of Hematology and Oncology,\n330 Brookline Avenue, MASCO 4th Floor, Boston, MA 02215, USA +1 617 632 9250"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, Division of Hematology and Oncology, 330 Brookline Avenue, MASCO 4th Floor, Boston, MA 02215, USA","institution_ids":["https://openalex.org/I1316535847"]},{"raw_affiliation_string":"+1 617 632 9260","institution_ids":[]},{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, Division of Hematology and Oncology,\n330 Brookline Avenue, MASCO 4th Floor, Boston, MA 02215, USA +1 617 632 9250","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5083614176","display_name":"Daniel C. Cho","orcid":"https://orcid.org/0000-0002-4248-6382","observed_orcids":["https://orcid.org/0000-0002-4248-6382"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel C Cho","raw_affiliation_strings":["Beth Israel Deaconess Medical Center, Division of Hematology and Oncology, 330 Brookline Avenue, MASCO 4th Floor, Boston, MA 02215, USA +1 617 632 9250; +1 617 632 9260; Dcho1@bidmc.harvard.edu","+1 617 632 9260","Beth Israel Deaconess Medical Center, Division of Hematology and Oncology,\n330 Brookline Avenue, MASCO 4th Floor, Boston, MA 02215, USA +1 617 632 9250"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, Division of Hematology and Oncology, 330 Brookline Avenue, MASCO 4th Floor, Boston, MA 02215, USA +1 617 632 9250; +1 617 632 9260; Dcho1@bidmc.harvard.edu","institution_ids":["https://openalex.org/I1316535847"]},{"raw_affiliation_string":"+1 617 632 9260","institution_ids":[]},{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, Division of Hematology and Oncology,\n330 Brookline Avenue, MASCO 4th Floor, Boston, MA 02215, USA +1 617 632 9250","institution_ids":["https://openalex.org/I1316535847"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1316535847"],"apc_list":null,"apc_paid":null,"fwci":0.1452,"has_fulltext":false,"cited_by_count":9,"citation_normalized_percentile":{"value":0.13114754,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"22","issue":"2","first_page":"285","last_page":"291"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.004999999888241291,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/perifosine","display_name":"perifosine","score":1.0},{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":0.9929999709129333},{"id":"https://openalex.org/keywords/alkylphospholipids","display_name":"alkylphospholipids","score":0.9300000071525574},{"id":"https://openalex.org/keywords/akt-inhibition","display_name":"AKT inhibition","score":0.800000011920929},{"id":"https://openalex.org/keywords/ph-domain","display_name":"pleckstrin homology domain","score":0.9819999933242798},{"id":"https://openalex.org/keywords/oral-anticancer-drugs","display_name":"oral anticancer drugs","score":0.6710000038146973},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6549999713897705},{"id":"https://openalex.org/keywords/molecularly-targeted-agents","display_name":"molecularly targeted agents","score":0.7590000033378601},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8149999976158142},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9269999861717224},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.8270000219345093}],"concepts":[{"id":"https://openalex.org/C2777472916","wikidata":"https://www.wikidata.org/wiki/Q1164529","display_name":"Renal cell carcinoma","level":2,"score":0.5703808665275574},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.47699931263923645},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4364067018032074},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3811858296394348},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.34078270196914673}],"mesh":[{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D010767","descriptor_name":"Phosphorylcholine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010767","descriptor_name":"Phosphorylcholine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D010767","descriptor_name":"Phosphorylcholine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D010767","descriptor_name":"Phosphorylcholine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D010767","descriptor_name":"Phosphorylcholine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015394","descriptor_name":"Molecular Structure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1517/13543784.2013.754422","doi":"https://doi.org/10.1517/13543784.2013.754422","is_oa":false,"landing_page_url":"https://doi.org/10.1517/13543784.2013.754422","pdf_url":null,"source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},{"id":"pmid:23253151","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23253151","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on investigational drugs","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":49,"referenced_works":["https://openalex.org/W1571056179","https://openalex.org/W1965645145","https://openalex.org/W1967884480","https://openalex.org/W1972943971","https://openalex.org/W1975722785","https://openalex.org/W1978377333","https://openalex.org/W1979649191","https://openalex.org/W1989040551","https://openalex.org/W1997932312","https://openalex.org/W1999966467","https://openalex.org/W2002659362","https://openalex.org/W2006941041","https://openalex.org/W2007959663","https://openalex.org/W2015417856","https://openalex.org/W2015823415","https://openalex.org/W2016757878","https://openalex.org/W2019558984","https://openalex.org/W2023823393","https://openalex.org/W2023952988","https://openalex.org/W2030711372","https://openalex.org/W2073084262","https://openalex.org/W2084469720","https://openalex.org/W2100669312","https://openalex.org/W2101628607","https://openalex.org/W2118677643","https://openalex.org/W2126386849","https://openalex.org/W2127339720","https://openalex.org/W2131857936","https://openalex.org/W2137132167","https://openalex.org/W2137208309","https://openalex.org/W2138129102","https://openalex.org/W2138504960","https://openalex.org/W2144625075","https://openalex.org/W2149360610","https://openalex.org/W2149456801","https://openalex.org/W2153624901","https://openalex.org/W2153867442","https://openalex.org/W2155319477","https://openalex.org/W2155691517","https://openalex.org/W2162424705","https://openalex.org/W2165404212","https://openalex.org/W2165948908","https://openalex.org/W2166779556","https://openalex.org/W2169634553","https://openalex.org/W2224470588","https://openalex.org/W2224540931","https://openalex.org/W2261566286","https://openalex.org/W2268972797","https://openalex.org/W4298379398"],"related_works":["https://openalex.org/W2284498467","https://openalex.org/W2224540931","https://openalex.org/W1571056179","https://openalex.org/W2524800756","https://openalex.org/W2258342243","https://openalex.org/W2153259757","https://openalex.org/W2063542678","https://openalex.org/W2246258464","https://openalex.org/W2228805137","https://openalex.org/W2590917519"],"abstract_inverted_index":{"INTRODUCTION:":[0],"Perifosine":[1,20],"is":[2,92],"an":[3],"oral":[4],"alkylphospholipid":[5],"which":[6],"has":[7,85],"recently":[8],"been":[9],"assessed":[10],"clinically":[11],"in":[12,57,70,89,109,128,132],"patients":[13,58],"with":[14,59,134],"advanced":[15,60],"renal":[16],"cell":[17,39],"carcinoma":[18],"(RCC).":[19],"acts":[21],"primarily":[22],"by":[23,29],"attenuating":[24],"the":[25,38,46,52,116],"activation":[26],"of":[27,49,55,64,74,105],"Akt":[28],"preventing":[30],"its":[31],"pleckstrin":[32],"homology":[33],"(PH)":[34],"domain-dependent":[35],"localization":[36],"to":[37,95],"membrane.":[40],"AREAS":[41],"COVERED:":[42],"This":[43],"review":[44],"summarizes":[45],"therapeutic":[47],"landscape":[48],"RCC":[50,71,110,129],"including":[51],"proposed":[53],"role":[54,127],"perifosine":[56,75,84,123],"RCC.":[61],"The":[62],"mechanism":[63],"action,":[65],"pharmacodynamics,":[66],"pharmacokinetics,":[67],"clinical":[68,87,107],"efficacy":[69,118],"and":[72,99,119],"safety":[73],"are":[76],"all":[77],"addressed":[78],"as":[79,111],"well.":[80],"EXPERT":[81],"OPINION:":[82],"Although":[83],"clear":[86],"activity":[88],"RCC,":[90],"it":[91],"not":[93,102],"superior":[94],"currently":[96],"available":[97],"agents":[98],"therefore":[100],"does":[101],"appear":[103],"worthy":[104],"further":[106],"development":[108],"a":[112,126],"single":[113],"agent.":[114],"Given":[115],"observed":[117],"mild":[120],"toxicity,":[121],"however,":[122],"may":[124],"have":[125],"therapy":[130],"given":[131],"combination":[133],"other":[135],"molecularly":[136],"targeted":[137],"agents.":[138]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2017,"cited_by_count":3},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}